The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO Breast 2021 | BrainStorm: improving prediction, diagnosis and management of brain metastases
Ahmad Awada, MD, PhD, Institute Jules Bordet, Brussels, Belgium, shares an update on the BrainStorm Program (NCT04109131), a clinical research platform which aims to optimize the treatment and management of patients with brain metastases. The study, which is performing MRIs and liquid biopsies and using cerebrospinal fluid (CSF) and circulating tumor DNA, aims to improve our understanding and prediction of the development of brain metastases, as well as enabling earlier diagnosis. This interview took place at the virtual European Society for Medical Oncology (ESMO) Breast Cancer Congress 2021.
Disclosures
Ahmad Awada, MD, PhD, has participated in an advisory role, has received institutional research grants, or has received speakers fees from Roche, Lilly, Amgen, EISAI, BMS, Pfizer, Novartis, MSD, Genomic Health, Ipsen, AstraZeneca, Bayer, Leo Pharma, Merck and Daiichi.
